Multiplex (assay)

A multiplex assay is a type of assay used in research to simultaneously measure multiple analytes (dozens or more) in a single run/cycle of the assay.[1] It is distinguished from procedures that measure one analyte at a time.

Multiplex assays within a given application area or class of technology can be further stratified based on how many analytes can be measured per assay, where "multiplex" refers to those with the highest number of analyte measurements per assay (up to millions) and "low-plex" or "mid-plex" refers to procedures that process fewer (10s to 1000s), though there are no formal guidelines for calling a procedure multi-, mid-, or low-plex based on number of analytes measured. Single-analyte assays or low-to-mid-plex procedures typically predate the rise of their multiplex versions, which often require specialized technologies or miniaturization to achieve a higher degree of parallelization.

Multiplex assays are widely used in functional genomics experiments that endeavor to detect or to assay the state of all biomolecules of a given class (e.g., mRNAs, proteins) within a biological sample, to determine the effect of an experimental treatment or the effect of a DNA mutation over all of the biomolecules or pathways in the sample. The ability to perform such multiplex assay experiments measuring large numbers of biomolecular analytes has been facilitated by the completion of the human genome sequence and that of many other model organisms.

"Multiplex" versus "high-throughput"

Multiplex assays are often used in high-throughput screening settings, where many specimens can be analyzed using a multiplex (or other) assay. Strictly speaking, a multiplex assay is not necessarily high-throughput. When the execution of a single multiplex assay generates data for a large number of analytes (e.g., gene expression levels for all genes in the human genome), it is considered high-throughput. However, the ability to rapidly process multiple samples in an automated fashion is what characterizes high-throughput techniques. Massive parallelization of assays is one way to achieve "high-throughput" status. Another way is via automation of manual laboratory procedures.

Example multiplex assay techniques

Nucleic acid-based multiplex techniques

Protein-based multiplex techniques

Other multiplex techniques

Laboratories performing multiplex assays

Eve Technologies is a world leader in Multiplexing assay technology.Many research studies requiring cytokine, chemokine or growth factor profiling, Eve Technologies Routine Discovery Assays are essential assays for Researchers all over the world. Routine Discovery Assay Services are performed on the broadest cytokine/chemokine multiplex kits and other biomarker panels for humans, mice, rats, and pigs.[7][8][9][10]

References

  1. Elshal, Mohamed F.; McCoy, J. Philip (2005-11-01). "Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA". Methods. 38 (4): 317. doi:10.1016/j.ymeth.2005.11.010.
  2. Tomaras, Georgia D.; Yates, Nicole L.; Liu, Pinghuang; Qin, Li; Fouda, Genevieve G.; Chavez, Leslie L.; Decamp, Allan C.; Parks, Robert J.; Ashley, Vicki C. (2008-12-15). "Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia". Journal of Virology. 82 (24): 12449–12463. ISSN 0022-538X. PMC 2593361Freely accessible. PMID 18842730. doi:10.1128/JVI.01708-08.
  3. Zolla-Pazner, Susan; deCamp, Allan; Gilbert, Peter B.; Williams, Constance; Yates, Nicole L.; Williams, William T.; Howington, Robert; Fong, Youyi; Morris, Daryl E. (2014-02-04). "Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection". PLOS ONE. 9 (2): e87572. ISSN 1932-6203. PMC 3913641Freely accessible. PMID 24504509. doi:10.1371/journal.pone.0087572.
  4. "Immunology Core: Binding Antibody Component | CFAR". cfar.duke.edu. Retrieved 2016-06-22.
  5. Ambroz K., (2006). "Improving quantitation accuracy for western blots".Image Analysis 09/2006.
  6. Laxman B, Morris DS, Yu J, et al. (February 2008). "A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer". Cancer Res. 68 (3): 645–9. PMC 2998181Freely accessible. PMID 18245462. doi:10.1158/0008-5472.CAN-07-3224.
  7. "Eve Technologies - scientist". app.scientist.com.
  8. Mineyko, Aleksandra, et al. "Inflammatory biomarkers of pediatric focal cerebral arteriopathy." Neurology 79.13 (2012): 1406-1408. http://www.neurology.org/content/79/13/1406.short
  9. Lu, Xiaoyan, et al. "Short-term exposure to engineered nanomaterials affects cellular epigenome." Nanotoxicology 10.2 (2016): 140-150. http://www.tandfonline.com/doi/abs/10.3109/17435390.2015.1025115
  10. Collins, K. H., et al. "Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development: studies in a rat model." Osteoarthritis and cartilage 23.11 (2015): 1989-1998. http://www.neurology.org/content/79/13/1406.short APA
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.